Clinical Trial

Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age

Name: Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age — clinical trial record (NCT07207408)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study will evaluate the immunogenicity, safety, and tolerability of rF1V-1018 vaccine

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-10-02.

Trial Details

NCT Number	NCT07207408
Lead Sponsor	Dynavax Technologies Corporation Collaborators: United States Department of Defense
Conditions	Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis
Enrollment	148 participants
Start Date	2025-09-11
Primary Completion	2027-01-29 (estimated)
Study Completion	2027-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-18